23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
23andMe and Nightingale Health have announced a strategic collaboration to pilot Nightingale’s blood metabolomics panel with 23andMe members. The partnership aims to enhance preventive health measures by integrating blood testing with 23andMe’s genetic services. The pilot will offer up to 5,000 23andMe+ Premium and Total Health members free access to Nightingale’s Remote Health Check, which measures biomarkers related to disease risk. The initiative seeks to combine genetic data with blood biomarkers to improve health predictions and interventions. The collaboration underscores both companies' commitment to proactive health management.
- 23andMe and Nightingale Health collaboration enhances preventive health service offerings.
- Up to 5,000 23andMe+ Premium and Total Health members receive free blood testing.
- Integration of blood biomarkers with genetic data improves health risk predictions.
- Pilot aims to evaluate customer feedback and utility of combined health data.
- Collaboration expands 23andMe's health service capabilities with Nightingale’s technology.
- Potential for enhanced customer lifetime health management through regular blood testing.
- None.
Insights
The collaboration between 23andMe and Nightingale Health has significant implications for the advancement of personalized healthcare. The integration of Nightingale’s blood metabolomics panel with 23andMe’s genetic testing and lifestyle tracking tools could lead to more precise and actionable health insights for users. Biomarkers like omega-3 and apolipoproteins, which are part of Nightingale’s panel, have established associations with cardiovascular health, inflammation and metabolic diseases. By incorporating these biomarkers, 23andMe can enhance its risk prediction models beyond genetic predispositions, offering a more comprehensive view of an individual’s health status. This holistic approach is a promising step toward preventive healthcare, enabling users to make informed lifestyle changes.
However, while the technology is promising, the success of this pilot will depend heavily on user adoption and the perceived accuracy and relevance of the data provided. Clinical validation and clear communication of the benefits to consumers will be crucial. In the short term, the impact on 23andMe’s stock may be neutral as investors wait to see user response and data from the pilot program. Long-term, if successful, it could position 23andMe as a leader in integrated health monitoring, potentially driving stock value higher.
From a market perspective, the collaboration between 23andMe and Nightingale Health is a strategic move to attract a broader customer base interested in proactive and preventive health measures. Offering blood testing at no cost to premium members is a strong incentive that may drive subscriptions and increase user engagement with 23andMe’s health platforms. This initiative aligns with the growing consumer demand for at-home health testing solutions, a market that has seen significant growth, especially post-pandemic.
Moreover, the ability to combine genetic data with blood biomarker data could differentiate 23andMe’s product offerings from competitors, potentially capturing a larger market share. However, the market response will hinge on the successful execution and reception of the pilot program. If 23andMe can demonstrate tangible health benefits and positive user feedback, this could enhance its competitive positioning and drive long-term growth. Investors should monitor key performance indicators such as user engagement rates, subscription growth and customer satisfaction metrics post-pilot.
SOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in biomarker testing and risk prediction, today announced a strategic collaboration to pilot Nightingale Health’s clinically-validated and cost-effective blood metabolomics panel with a cohort of 23andMe members.
Nightingale’s Remote Health Check accurately measures dozens of biomarkers from a single blood sample, including cholesterols, apolipoproteins and fatty acids like omega-3. Many of these blood biomarkers have established clinical relationships to disease and can help guide important lifestyle interventions – such as diet and exercise. This pilot marks an important milestone in making blood testing more efficient and accessible.
23andMe currently offers its annual members the option for blood testing and provides interactive tools like HealthTracks, a feature that incorporates customer lifestyle choices into calculating a lifetime risk of disease. Blood biomarkers may improve the accuracy of these predictions and provide more direct insight into the kinds of interventions that may be most impactful to a customer’s health.
As part of the pilot, 23andMe will offer up to 5,000 23andMe+ Premium and Total Health members the opportunity to receive blood testing through Nightingale’s Remote Health Check at no cost to them. The pilot will evaluate customer feedback around blood testing, at-home sample collection, and the utility of the data when coupled with 23andMe’s established personal genetics products.
23andMe and Nightingale Health have a shared vision to help individuals identify health risks and prevent disease through proactive testing, treatment, coaching and behavior change. Together, the companies’ technologies allow for a more comprehensive assessment of a customer’s health and continuous tracking of progress toward their goals.
“We are truly impressed with Nightingale Health’s capabilities in blood biomarker testing. Their work with public biobank projects and resulting publications have previewed the exciting potential for metabolomics in prediction. We believe this collaboration will ultimately help our customers lead longer, healthier lives,” said Anne Wojcicki, CEO and Co-Founder of 23andMe. “We are enthusiastic about long-term opportunities that combine the power of our technologies.”
“This collaboration enables a globally unique feature set for 23andMe’s consumer health services. Together, we can help customers track and improve their health with regular blood testing using Nightingale Health’s technology,” said Teemu Suna, CEO and Founder of Nightingale Health. “This marks an important step in the execution of Nightingale Health’s strategy, as it announces an important partnership providing access to the consumer health market.”
About 23andMe
23andMe is a genetics-led consumer healthcare and therapeutics company empowering a healthier future. For more information, please visit www.23andme.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including. All statements, other than statements of historical fact, included or incorporated in this press release are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," “predicts,” "continue," "will," “schedule,” and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe’s current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe’s forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23andMe), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, and as revised and updated by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The statements made herein are made as of the date of this press release and, except as may be required by law, 23andMe undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.
For further information, please contact:
23andMe
press@23andme.com
investors@23andme.com
FAQ
What is the collaboration between 23andMe and Nightingale Health about?
When was the 23andMe and Nightingale Health collaboration announced?
What benefits do 23andMe members receive from the collaboration with Nightingale Health?
How does the pilot program integrate with 23andMe's existing services?
What technology does Nightingale Health bring to the collaboration with 23andMe?
How many 23andMe members will participate in the blood testing pilot?
